David Franco, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 27.4% of the total. 2025 is the largest year on record at $1,009, more than ten times the $14 reported in 2020.
Across 121 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$757
- Bristol Myers Squibb$252
- Boston Scientific$159
- Teva Pharmaceuticals USA, Inc.$138
- Genentech USA, Inc.$133
- Argenx US, Inc.$126
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,758100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $757 |
| Bristol Myers Squibb | 16 | $252 |
| Boston Scientific | 2 | $159 |
| Teva Pharmaceuticals USA, Inc. | 7 | $138 |
| Genentech USA, Inc. | 5 | $133 |
| Argenx US, Inc. | 5 | $126 |
| Vanda Pharmaceuticals Inc. | 4 | $125 |
| Biogen | 1 | $89 |
| GE HealthCare | 3 | $84 |
| UCB, Inc. | 4 | $83 |
| Cycle Pharmaceuticals Inc | 4 | $76 |
| Lundbeck LLC | 3 | $71 |
| EMD Serono, Inc. | 3 | $70 |
| Amneal Pharmaceuticals LLC | 3 | $67 |
| Amgen | 3 | $64 |
| Kyowa Kirin, Inc. | 3 | $55 |
| CSL Behring | 2 | $52 |
| SK Life Science, Inc. | 2 | $51 |
| Lilly USA, LLC | 3 | $51 |
| TG Therapeutics, Inc. | 1 | $43 |
| Johnson & Johnson | 2 | $41 |
| Eisai Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Abbott | 1 | $24 |
| Pfizer | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$146
How this compares
$2,758 in reported general payments places this provider in the 60th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 22 | $25,430 |
| Lamotrigine ErLamotrigine | 11 | $25,248 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $12,045 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 194 | $6,137 |
| Midodrine Hcl | 14 | $2,495 |
| Levetiracetam ErLevetiracetam | 56 | $2,384 |
| Primidone | 80 | $2,323 |
| AmantadineAmantadine Hcl | 40 | $1,974 |
| Carbamazepine | 26 | $1,943 |
| Divalproex Sodium | 17 | $1,731 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 59 | $1,604 |
| Lacosamide | 25 | $1,556 |
| Carbamazepine ErCarbamazepine | 17 | $1,506 |
| Oxcarbazepine | 25 | $1,148 |
| Gabapentin | 53 | $1,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $18 | $25,43022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 105 neurology providers in Nebraska.
Other neurology in Omaha
- Chad WhyteOmaha$647K
- Scott GoodmanOmaha$377K
- Rana ZabadOmaha$276K
- Deepak MadhavanOmaha$189K
- Pamela SantamariaOmaha$90K
- Peter SohOmaha$60K
- Kiel WoodwardOmaha$32K
- Pierre FayadOmaha$24K
- Jonathan MoravekOmaha$19K
- Erin SmithOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.